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ABSTRACT: Cardiomyopathy is a manifestation of transthyretin 
amyloidosis (ATTR), which is an underrecognized systemic disease 
whereby the transthyretin protein misfolds to form fibrils that 
deposit in various tissues and organs. ATTR amyloidosis is debilitating 
and associated with poor life expectancy, especially in those with 
cardiac dysfunction, but a variety of treatment options have recently 
become available. Considered a rare disease, ATTR amyloidosis 
may be more prevalent than thought, particularly in older persons. 
Diagnosis is often delayed because of a lack of disease awareness 
and the heterogeneity of symptoms at presentation. Given the recent 
availability of effective treatments, early recognition and diagnosis 
are especially critical because treatment is likely more effective earlier 
in the disease course. The Amyloidosis Research Consortium recently 
convened a group of experts in ATTR amyloidosis who, through an 
iterative process, agreed on best practices for suspicion, diagnosis, 
and characterization of disease. This review describes these consensus 
recommendations for ATTR associated with cardiomyopathy as 
a resource to aid cardiologists and others in the recognition and 
diagnosis of ATTR associated with cardiomyopathy. Included in 
this review is an overview of red flag signs and symptoms and a 
recommended diagnostic approach, including testing for monoclonal 
protein, scintigraphy, or biopsy and, if ATTR associated with 
cardiomyopathy is identified, TTR genotyping.
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Transthyretin amyloidosis (ATTR) is a disease caused by abnormal fibrils derived from TTR (transthyre-tin), a protein produced mainly by the liver, which 
aggregate and deposit in tissues and organs.1 Cardiomy-
opathy is a common manifestation of ATTR amyloidosis 
(ATTR associated with cardiomyopathy [ATTR-CM]) and 
is associated with a particularly poor life expectancy of 
2 to 6 years after diagnosis.2 Patients with ATTR-CM 
experience debilitating physical symptoms common to 
heart failure (HF), such as exercise intolerance and fa-
tigue, which result in decreased functional capacity, di-
minished quality of life, and eventual death.3 ATTR-CM 
can be acquired through aggregation of wild-type TTR 
(ATTRwt) or inherited from a variety of genetic variants 
of TTR (mutant transthyretin amyloidosis [ATTRm]; also 
known as hereditary ATTR).
ATTRm is considered rare and is transmitted in an 
autosomal-dominant manner and with variable pene-
trance. Certain variants typically result in cardiomyopa-
thy, whereas others typically result in polyneuropathy, 
although cardiomyopathy and polyneuropathy mani-
festations may overlap (Figure 1). The prevalence of car-
diomyopathy among persons with ATTRm is estimated 
at ≈40 000 of the 50 000 persons with ATTRm globally,4 
but this may be an underestimate.
The most common worldwide TTR variant, Val122Ile 
(or pV142I), occurs in ≈3% to 4% of black Americans, 
with undefined phenotypic penetrance.5,6 This Val122I-
le TTR variant manifests predominantly as cardiomy-
opathy,7 and 1 estimate shows 10% of black Ameri-
cans with HF who are older than 60 are carriers of the 
Val122Ile TTR variant.8 Thr60Ala, another common TTR 
variant, often manifests as a mixed phenotype, includ-
ing cardiomyopathy, polyneuropathy, and gastrointes-
tinal dysfunction and is present in ≈1% of persons in 
northwest Ireland.9 The Val30Met variant is the most 
common cause of ATTRm with polyneuropathy; how-
ever, late-onset ATTRm in patients of the Val30Met 
variant typically manifests as cardiomyopathy. Pheno-
typic penetrance of ATTRm is clearly age dependent; 
thus, ascertainment of population prevalence varies 
depending on age.
The true prevalence of ATTRwt is unknown; it may 
be relatively high compared with the prevalence of 
ATTRm. In autopsy studies, ≈25% of the hearts of per-
sons 80 years or older contained wild-type TTR fibrils, 
regardless of the presence of symptoms.4,10 Studies 
using nonbiopsy approaches to diagnosis demonstrate 
a TTR prevalence of 16% among patients undergoing 
percutaneous aortic valve replacement for severe aortic 
stenosis,11 13% among patients with heart failure with 
a preserved ejection fraction,12 5% among patients 
with presumed hypertrophic cardiomyopathy,13 and 7% 
to 8% among patients with carpal tunnel syndrome on 
biopsy of the tenosynovial tissue.14 Furthermore, ≈1% 
to 3% of persons older than 75 showed myocardial 
retention of the diphosphono-1,2-propanodicarboxylic 
acid, which is indicative of TTR cardiac amyloidosis.15,16
Delays in diagnosis of ATTR-CM amyloidosis com-
monly occur because of physician- and disease-related 
reasons, including fragmented knowledge among dif-
ferent specialists and subspecialists, shortage of centers 
and specialists dedicated to disease management, erro-
neous belief that it is an incurable disease, perceived 
rarity of the condition, intrinsic phenotypic and geno-
typic heterogeneity, and, in some cases, the necessity of 
target organ tissue histological diagnosis.12,17,18
The Amyloidosis Research Consortium recently led the 
development of a comprehensive set of consensus rec-
ommendations for the suspicion and diagnosis of ATTR 
amyloidosis. These recommendations were developed 
in collaboration with companies conducting research in 
ATTR amyloidosis (GSK, Ionis, Pfizer, and Alnylam) and 
through an iterative process with key specialists in amy-
loidosis. They also reflect collaboration and consensus 
among key amyloidosis experts of best practices for 
diagnosis and characterization of the disease.
This review describes the consensus recommenda-
tions for ATTR-CM amyloidosis with a goal of providing 
clinicians with an overview of key aspects of ATTR-CM 
Figure 1. Genotype–phenotype correlations in mutant transthyretin amyloidosis.  
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diagnosis to help facilitate rapid and accurate identifi-
cation of the disease. Focus is placed on disease presen-
tation, characterization, and challenges for early and 
accurate diagnosis.
MISDIAGNOSIS AND RAISING 
SUSPICION
Misdiagnosis
Because they are considered rare and typically manifest 
with heterogeneous symptoms similar to those of other 
more common diseases, ATTRm and ATTRwt amyloi-
dosis can be difficult to diagnose. Unexplained senso-
rimotor neuropathy or autonomic symptoms, such as 
orthostasis, erectile dysfunction, sweating abnormali-
ties, and diarrhea, may lead to many lengthy and unfo-
cused medical evaluations before amyloid is discovered. 
Depending on the mutation, patients with ATTR-CM 
show common signs and symptoms of HF, such as 
dyspnea, orthopnea, paroxysmal nocturnal dyspnea, 
edema, fatigue, exercise intolerance, dizziness/syncope, 
palpitations, electrical conduction abnormalities, and 
arrhythmias. Therefore, ATTR-CM is sometimes mistak-
enly diagnosed as hypertrophic cardiomyopathy13 or as 
generic, undifferentiated heart failure with preserved 
ejection fraction rather than as amyloidosis.12
It is significant that in addition to symptoms of 
cardiomyopathy, other systemic phenotypes such as 
polyneuropathy and gastrointestinal disorders may be 
present. Because of the age-dependent development 
of ATTR-CM, many patients have true comorbid con-
ditions including hypertension, diabetes mellitus, isch-
emic heart disease, or aortic stenosis (particularly low 
flow-low gradient) before amyloidosis develops. In this 
context, a high degree of clinical suspicion is necessary 
to identify incident ATTR-CM.
Signs and Symptoms
The spectrum of clinical presentations in patients with 
ATTR amyloidosis obliges all clinicians to be aware of 
common disease patterns (Table 1; Figure 2), addition-
al clues, and commonly affected populations. Suspi-
cion of ATTR-CM should be triggered in older persons 
who have been hospitalized for HF, elevated troponin 
levels, or levels of NT-proBNP (N-terminal pro-brain 
natriuretic peptide) that are out of proportion to 
the clinical context. Other hints of ATTR amyloidosis 
include hypertension that resolves over time and an 
intolerance of ACE (angiotensin-converting enzyme) 
inhibitors, angiotensin receptor blockers, or β block-
ers. In addition, though not infrequent in the general 
population, carpal tunnel syndrome occurs particularly 
frequently among males with ATTR.19 Lumbar spinal 
stenosis,20,21 previous orthopedic procedures,22 and 
spontaneous biceps tendon rupture23 may also be ear-
ly indicators of ATTR-CM.
Biomarkers
No plasma or urinary biomarker is available for the diag-
nosis of ATTR. Nevertheless, in the clinical arena, the 
combination of very high plasma levels of NT-proBNP 
(disproportionate compared with the degree of HF) 
and elevated troponin levels in a patient with echocar-
diographic hypertrophic phenotype is strongly sugges-
tive of amyloidotic cardiomyopathy and can prompt 
the diagnostic workup. NT-proBNP is a biomarker that 
is elevated early in ATTRm amyloidosis before cardiac 
symptoms appear, especially among asymptomatic car-
riers of a TTR gene mutation or patients with neuro-
logical symptoms only.24 In addition, the usefulness of 
Table 1. Diagnostic Clues to ATTR-CM
History/examination clues
  Evidence of right-sided heart failure (eg, hepatomegaly, ascites, and 
lower extremity edema)
  HFpEF, particularly in men
  Intolerance to ACE inhibitors or beta blockers
  Bilateral carpal tunnel syndrome
  Lumbar spinal stenosis
  Biceps tendon rupture
  Unexplained peripheral neuropathy (eg, loss of warm/cold 
discrimination), particularly if associated with autonomic dysfunction 
(eg, postural hypotension, alternating bowel pattern)
  Unexplained atrial arrhythmias or conduction system disease/need for a 
pacemaker
Imaging clues
  Myocardial uptake on PYP/DPD or HMDP imaging
  Infiltrative phenotype (eg, biventricular hypertrophy pericardial effusion, 
valve thickening, interatrial septal thickening)
  Diffuse subendocardial or transmural LGE or increased ECV fraction on 
cardiac MRI
  Apical sparing on longitudinal strain imaging
  Low myocardial contraction fraction
  Restrictive LV filling with RV wall thickening
Combined clues
  HF with unexplained increased LV wall thickening and nondilated LV
  Concentric LV wall thickening, possibly with an abnormal QRS voltage-
to-LV thickness ratio
  Depressed longitudinal LV function despite normal EF
  Aortic stenosis with RV thickening, particularly if paradoxical low flow/
low gradient
The sensitivity and specificity of these clues has not been delineated in 
population-based samples with heart failure. ACE indicates angiotensin-
converting enzyme; ATTR-CM, transthyretin amyloidosis with predominant 
cardiomyopathy; DPD, diphosphono-1,2-propanodicarboxylic acid; ECV, 
extracellular volume; EF, ejection fraction; HF, heart failure; HFpEF, heart failure 
with preserved ejection fraction; HMDP, hydroxymethylene diphosphonate; 
LGE, late gadolinium enhancement; LV, left ventricular; MRI, magnetic 
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circulating retinol binding protein 4 in conjunction with 
electrocardiographic and echocardiographic measures 
to identify patients with HF who have ATTR cardiac 
amyloidosis from the Val122Ile mutation has recently 
been reported.25
Electrocardiography and Cardiac Imaging
Electrocardiography is a broadly available screening 
test, and findings may reveal abnormalities associated 
with ATTR-CM (eg, low voltage) that are classically 
described in patients with cardiac amyloidosis.26–28 
However, low voltage is less common in cardiac amy-
loidosis than a pseudoinfarct pattern of Q waves 
unrelated to prior myocardial infarctions.27 Given that 
low QRS voltage has been seen in ≈50% of patients 
with AL amyloidosis and in ≈25% of patients with 
ATTR amyloidosis, its usefulness as a screening test is 
limited by low sensitivity.27 More commonly, cardiac 
amyloidosis is hallmarked by QRS voltages that are 
disproportionate to the thickness of the left ventricu-
lar (LV) wall, which can be assessed using a ratio of 
QRS voltage to LV wall thickness.29,30 The presence of 
left ventricular hypertrophy on electrocardiography 
does not exclude ATTR-CM.
Echocardiography is cost-effective, commonly 
available, relatively quick to perform, and better 
than most other imaging techniques at identifying 
diastolic dysfunction. Although all are not invariably 
present, classic echocardiography findings of infiltra-
tive disease include LV wall thickening, small LV cavity 
size, biatrial enlargement, thickened valves, elevated 
right ventricular systolic pressure and atrial septum 
thickness, granular sparkling appearance of the myo-
cardial wall, pericardial effusion, restrictive transmi-
tral Doppler filling pattern, and reduced ventricular 
strain, apical-to-basal strain ratio >2.1, LV ejection 
fraction-to-strain ratio >4 (Figures  2 and 3).26,31,32 
Combining electrocardiography (low voltage) and 
echocardiography (LV septal thickness above the 
upper limit of normal, especially >12 mm) is particu-
larly useful for increased clinical suspicion of ATTR-
CM33 (Table 1; Figure 2).
Similarly, cardiac magnetic resonance (CMR) can 
show detailed information about systolic function and 
cardiac structure (Figure 3). The advantage of CMR is 
its unique ability to enable tissue characterization,34,35 
allowing it to differentiate amyloidosis from nonamy-
loid wall-thickening disorders. On tissue characteriza-
tion, the typical CMR findings of cardiac amyloido-
sis include diffuse subendocardial or transmural late 
gadolinium enhancement on late gadolinium imaging 
with nulling of the blood pool and elevated native T1 
and extracellular volume on T1 mapping sequences. 
T1 mapping, a relatively new and quantitative CMR 
technique, with native T1 and extracellular volume, 
has the potential to longitudinally monitor disease 
progression.35,36
Myocardial scintigraphy with bone avid tracers 
99mtechnetium pyrophosphate (99mTc-pyrophosphate), 
99mtechnetium 3,3-diphosphono-1,2-propanodicarbox-
ylic acid (99mTc-diphosphono-1,2-propanodicarboxylic 
acid), and 99mtechnetium hydroxymethylene diphos-
phonate (99mTc-hydroxymethylene diphosphonate) has 
high sensitivity and specificity for ATTR-CM and may 
help with the early diagnosis of ATTR-CM (Figures  4 
and 5).37–43 Ease of access, simplicity of imaging, rela-
tively low cost, and specificity for cardiac ATTR amy-
loid deposits are some of the advantages of myocardial 
scintigraphy compared with echocardiography, CMR, 
Figure 2. Proposed timeline of appropriate diagnostic tests based on typical disease process.  
11C-PIB indicates Pittsburgh compound B; 99mTc-DPD, 99mtechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid; 99mTc-HMDP, hydroxymethylene diphosphonate; 
99mTc-PYP, technetium pyrophosphate; ATTR-CM, transthyretin amyloidosis with predominant cardiomyopathy (either wild-type or hereditary); CA, cardiac amyloi-
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and endomyocardial biopsy. In addition, the utility of 
these agents in identifying ATTR-CM before increases 
in wall thickness are observed or electrocardiographic 
voltage is reduced15,41,44,45 suggests that they may be 
useful for early identification of affected individuals. 
Molecular imaging with targeted amyloid-binding posi-
tron emission tomography radiotracers 11C-Pittsburgh 
compound B (11C-PIB),18F-florbetapir, and 18F-florbe-
taben is an emerging quantitative diagnostic approach 
that may distinguish cardiac amyloidosis from other 
forms of heart disease.46–49
DIAGNOSIS AND ASSESSMENT
A diagnostic approach for patients with suspected car-
diac amyloidosis should include testing for monoclonal 
protein followed by scintigraphy or biopsy (Figure 6).50 
Clinicians should note that up to 40% of patients 
with ATTR-CA can have a monoclonal gammopathy of 
unknown significance51 and in this setting scintigraphy 
alone cannot ensure a diagnosis with 100% specific-
ity. Nuclear imaging can also be performed concur-
rent to AL assessment, even in the case of a detected 
Figure 3. Typical echocardiography and cardiac magnetic resonance (CMR) findings in a patient with cardiac amyloidosis.  
Parasternal longitudinal axis (A) and apical 4-chamber (B) echocardiography views show considerably increased left ventricular wall thickness in the absence of 
ventricular dilation; the myocardial walls seem hyperechogenic. Other characteristic findings include biatrial enlargement and thickening of valve leaflets (A and 
B) of the interatrial septum (B) and right ventricle-free wall (C). A generalized small pericardial effusion is also noticeable (A–C). The profile of left ventricle (LV) 
filling (D) is restrictive, with markedly elevated E wave, reduced A wave, and decreased deceleration time. A decreased E’ wave measurement can be observed on 
lateral wall tissue Doppler imaging (E). The longitudinal systolic function is impaired with decreased S’ measurement on lateral wall tissue Doppler imaging (E) and 
markedly reduced longitudinal strain evident on the apical 4-chamber view (F). LV longitudinal strain (F) is preserved at the LV apex but is significantly impaired at 
the midbasal segments. Each colored curve shows longitudinal strain at 1 of the 6 LV measured segments. Dotted line is the mean. Color map represents the 6 
LV segments, with time corresponding to the x axis. The bullseye appearance (with apex at the center of the color-coding map) is typical of cardiac amyloidosis. 
Cardiac magnetic resonance images (G) include 4-chamber cine, corresponding native T1 maps, late gadolinium enhancement (LGE) image with phase-sensitive 
reconstruction, and extracellular volume (ECV) maps in a patient with no cardiac amyloidosis (upper row) and 2 patients with cardiac amyloidosis (middle row and 
bottom row). In the upper row, the patient with no cardiac amyloidosis has no LGE and normal native T1 and ECV maps; in the middle row, the patient with car-
diac amyloidosis has subendocardial LGE, elevated T1 values, and elevated ECV values; in the bottom row, the patient with cardiac amyloidosis has a high cardiac 
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monoclonal gammopathy, for additive information. 
However, in the context of monoclonal gammopa-
thy of unknown significance, endomyocardial biopsy 
is necessary to definitively diagnose ATTR-CM. If no 
monoclonal protein is detected and a diagnosis of AL 
cardiac amyloidosis is excluded, radionuclide scintigra-
phy alone, without myocardial biopsy, can be used to 
diagnose ATTR-CM.37 Among all radiotracers that have 
been tested, diphosphono-1,2-propanodicarboxylic 
acid, pyrophosphate, and hydroxymethylene diphos-
phonate are recommended for the diagnosis of amy-
loidosis (Table 2).52,53 The radiotracer 123I-metaiodoben-
zylguanidine can detect sympathetic innervation of the 
heart and may indicate cardiac amyloid,63–66 although 
123I-metaiodobenzylguanidine imaging is also abnormal 
in other cardiac conditions and is not specific enough 
to diagnose ATTR-CM. If ATTR-CM is identified, TTR 
genotyping should be performed.
Figure 4. 99mTechnetium imaging procedures for cardiac amyloidosis.  
SPECT imaging to identify myocardial retention of technetium-based isotopes is particularly useful in discriminating blood pool on planar scans that result in in a 
false-positive test from myocardial uptake of the isotope indicative of transthyretin amyloidosis with cardiomyopathy. 99mTechnetium-pyrophosphate imaging for 
transthyretin cardiac amyloidosis. Adapted with permission of the American Society of Nuclear Cardiology. ©2018, American Society of Nuclear Cardiology.
Figure 5. Semiquantitative approach to 99mTc-PYP/DPD/HMDP imaging in cardiac amyloidosis.  
Semiquantitative methods to generate heart-to-contralateral (HCL) ratios with a target region of interest (ROI) over the heart (A, B, red arrows) mirrored over the 
contralateral chest for a background ROI (A, B, green arrows). An HCL ratio of >1.5 on 1-h imaging is diagnostic of transthyretin amyloidosis with predominant 
cardiomyopathy (ATTR-CM). Comparatively, 99mTc DPD includes a whole-body scan, 25 to 30 mCi of radiotracer, 200 min of study time, with heart-to-whole-body 
ratios generated by a target ROI over the heart (C, D, red arrows) as well as background ROIs over the kidneys and bladder (C, D, green arrows). C and D, Adapted 
from Perugini et al39 with permission. Copyright ©2005, Journal of the American College of Cardiology.99mTc hydroxymethylene diphosphonate was validated for 
diagnosing ATTR CA, and representative scans show diffuse myocardial uptake in a patient with cardiac transthyretin amyloidosis at baseline. 99mTc-DPD indicates 
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If monoclonal protein is detected, assessments should 
include amyloid typing of a tissue biopsy from a clinically 
affected organ (eg, endomyocardial biopsy if the heart 
is clinically affected), abdominal fat, or bone marrow, 
depending on availability and expertise at the clinic. TTR 
genotyping should be performed if a diagnosis of ATTR 
amyloidosis is made on biopsy. Endomyocardial biopsy 
is invasive, carries a small risk for serious complications, 
and requires technical expertise, whereas fat pad biopsy 
is less invasive and poses little risk but has varying sen-
sitivity in ATTR-CM (with roughly 45% sensitivity for 
ATTRm and roughly 15% sensitivity for ATTRwt).67 Given 
the high false-negative rate from biopsies of nonclinically 
involved sites (eg, fat pad, bone marrow), further evalu-
ation is warranted even in the presence of a negative 
biopsy from such sites if clinical suspicion remains elevat-
ed. In such cases, biopsy of a clinically affected organ (eg, 
endomyocardial biopsy) is imperative. Endomyocardial 
biopsy assessment with Congo red staining has ≈100% 
specificity and sensitivity for detecting amyloid deposits 
and is still considered the gold standard in situations with 
equivocal noninvasive findings.68 Regardless of the site 
of biopsy, amyloid deposits must then undergo either 
immunofluorescence or mass spectrometry to confirm 
the amyloidosis subtype (eg, AL or ATTR).
In patients with confirmed ATTR amyloidosis, TTR gene 
sequencing is necessary even if they do not have a fam-
ily history of amyloidosis or evidence of polyneuropathy 
because the penetrance of ATTRm varies among the vari-
ants and families. If a TTR variant is detected, genetic 
counseling for relatives of the affected patient is indicated.
Prognostic Stratification Using 
Biomarkers
Natriuretic peptides and cardiac troponins, though not 
specific markers of ATTR-CM, are well established to 
assess risk (eg, Mayo staging) and to evaluate response 
to treatment in patients with AL amyloidosis.69–71 How-
ever, evidence in AL amyloidosis may not apply to ATTR 
Figure 6. Diagnostic algorithm for patients with suspected cardiac amyloidosis.  
Note that urine protein electrophoresis with immunofixation can be performed on spot or 24-h urine collection. AL indicates light chain amyloidosis; ATTR, 
transthyretin amyloidosis; ATTRm, mutant transthyretin amyloidosis; ATTRwt, wild-type transthyretin amyloidosis; ECG, electrocardiography; Echo, echocardiogram; 
MGUS, monoclonal gammopathy of undetermined significance; MRI, magnetic resonance imaging. Adapted from Nativi-Nicolau and Maurer50 with permission. 
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amyloidosis because the 2 diseases have substantially 
different biologies.29,72,73 Different staging systems for 
ATTRwt amyloidosis and ATTR-CM have been proposed. 
A proposed system in patients with ATTRwt includes NT-
proBNP (>3000 pg/mL) and troponin T (>0.05 ng/mL).74 
The most recently proposed system for staging ATTR-CM 
(including ATTRwt and ATTRm) uses NT-proBNP (>3000 
pg/mL) and estimated glomerular filtration rate (<45 mL/
minute).75 Staging in both systems is defined such that 
stage 1 does not meet either threshold, stage 2 meets 1 
of the 2 thresholds, and stage 3 meets both thresholds.
FUTURE DIRECTIONS
To reduce the delays in diagnosis of this important health 
problem, specific programs for screening or early iden-
tification should be studied that leverage techniques 
having appropriate sensitivity and specificity as well as 
favorable cost/benefit. Implementation of appropriate 
screening programs for ATTR-CM will need to include 
factors such as whether there are methods and facili-
ties available for diagnosis, whether certain diagnostic 
tests are acceptable to those at risk, and the particular 
test characteristics, as well as cost and benefits of treat-
ments and when appropriate timing would be for the 
intervention. Given that prognosis is highly dependent 
on the underlying cardiac dysfunction coupled with 
the recently available treatments for ATTR amyloidosis, 
screening programs may become important.
CONCLUSIONS
ATTR amyloidosis is a progressive disease associated with 
increased morbidity and mortality and occurs in inherited 
(ATTRm or hereditary ATTR) or acquired (ATTRwt) forms. 
Disease-related cardiac dysfunction in patients with ATTR 
amyloidosis is associated with particularly poor outcomes 
and is a manifestation of many of the genetic variants 
and the wild-type form of ATTR amyloidosis.
Diagnosis of ATTR-CM is often missed or mistaken as 
hypertrophic cardiomyopathy or heart failure with pre-
served ejection fraction of unknown cause. Although 
considered a rare disease, the true prevalence of ATTR-
CM is unclear and is likely higher than appreciated. 
Physicians should consider systemic signs and symp-
toms along with evidence from biomarkers and imag-
ing to build suspicion for ATTR-CM. To facilitate early 
diagnosis of ATTR-CM, evaluation of myocardial uptake 
on bone scintigraphy should be considered in patients 
with HF, unexplained neuropathy, family history of amy-
loidosis, or unexplained increased LV wall thickness. 
Appropriate evidence on echocardiography or cardiac 
MRI—combined with no light chain clone, grade ≥2 
myocardial uptake of 99mTc-pyrophosphate, diphos-
phono-1,2-propanodicarboxylic acid, and hydroxy-
methylene diphosphonate—is diagnostic of ATTR-CM, 
in which case endomyocardial biopsy is unnecessary. 
Genetic testing should be performed to differentiate 
ATTRm from ATTRwt causes of ATTR-CM.







Uptake Imaging Capability Considerations
Bone avid tracers primarily used in the United States
99mTc-PYP44,54–57 Planar/SPECT Bone tracer ATTR-CM Diagnostic; possibly early 
detection
Some uptake in patients with 
AL amyloidosis, less than ATTR 
amyloidosis
Bone avid tracers primarily used outside the United States
99mTc-DPD39–41 and 
99mTc-HMDP38,58,59
Planar/SPECT Bone tracer ATTR-CM Diagnostic; possibly early 
detection and disease 
monitoring
Some uptake in patients with 
AL amyloidosis, less than ATTR 
amyloidosis
Amyloid-binding radiotracers
11C-PIB47,60,61 PET Amyloid deposits ATTR-CM, AL 
amyloidosis
Possibly quantitation of amyloid 
burden, disease monitoring
Short half-life, expensive isotope 
relative to SPECT tracers
18F-florbetapir48,62 PET Amyloid deposits ATTR-CM, AL 
amyloidosis
Possibly early detection, 
quantitation, and disease 
monitoring
Expensive isotope relative to 
SPECT tracers
18F-florbetaben49 PET Amyloid deposits ATTR-CM, AL 
amyloidosis
Possibly early detection, 
quantitation, and disease 
monitoring
Expensive isotope relative to 
SPECT tracers
18F-NaF52,53 PET Bone tracer Equivocal ATTR-CM Possibly early detection, 
quantitation, and disease 
monitoring
No uptake in patients with AL 
amyloidosis, equivocal uptake in 
patients with ATTR-CM
The tracers 99mTc-MDP and 99mTc-aprotinin are not recommended. 11C-PIB indicates Pittsburgh compound B; 18F-NaF, sodium fluoride; 99mTc-DPD, 99mtechnetium-
3,3-diphosphono-1,2-propanodicarboxylic acid; 99mTc-HMDP, hydroxymethylene diphosphonate; 99mTc-PYP, technetium pyrophosphate; 123I, iodine-123; AL, amyloid 
light chain; ATTR-CM, transthyretin amyloidosis with predominant cardiomyopathy (either wild-type or hereditary); PET, positron emission tomography; and SPECT, 
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The consensus recommendations described in this 
review were developed with the goal of providing cli-
nicians with an overview of key aspects of ATTR-CM 
diagnosis. We hope these recommendations facilitate 
early, rapid, and accurate identification of ATTR-CM to 
allow implementation of targeted, disease-modifying 
treatment and improved outcomes for patients.
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